Dermatoprotective Effect of Ocoxin Cream® in Cancer Patients Treated with Radiation Therapy. Case Series  

作　　者：Iris B. Inguanzo-Valdés Helga Candanedo-Pazo Aixa Ulloa-Balmaseda Oslay Cervantes-Hernández Acralis de La Cruz-Galguera Martha Lugioyo-Lugo Rosa M. Ortiz-Reyes Mircea Betancourt-Cabeza Jorge Luis Soriano-García Ramón Ropero-Toirac Iris B. Inguanzo-Valdés;Helga Candanedo-Pazo;Aixa Ulloa-Balmaseda;Oslay Cervantes-Hernández;Acralis de La Cruz-Galguera;Martha Lugioyo-Lugo;Rosa M. Ortiz-Reyes;Mircea Betancourt-Cabeza;Jorge Luis Soriano-García;Ramón Ropero-Toirac(Department of Radiation Therapy, National Institute of Oncology and Radiobiology, Havana, Cuba;Clinical Research Department, National Institute of Oncology and Radiobiology, Havana, Cuba;Scientific Department, Catalysis S.L., Madrid, Spain)

机构地区：[1]Department of Radiation Therapy, National Institute of Oncology and Radiobiology, Havana, Cuba [2]Clinical Research Department, National Institute of Oncology and Radiobiology, Havana, Cuba [3]Scientific Department, Catalysis S.L., Madrid, Spain

出　　处：《Case Reports in Clinical Medicine》2025年第1期25-39,共15页临床医学病理报告(英文)

摘　　要：Background: The effects of radiation therapy can impact patients’ quality of life, leading to treatment interruptions and therefore sub-optimal outcomes. The main aim was to evaluate the preliminary effects of Ocoxin cream® in the prevention of radiation therapy. Methods: Fifty patients were enrolled in an observational, longitudinal, prospective, single-centre clinical trial in the Department of Radiation Therapy at the National Institute of Oncology and Radiobiology in Havana, Cuba. The Radiation Therapy Oncology Group (RTOG) toxicity criteria were used to classify the radiation therapy, and the Dermatology Life Quality Index (DLQI) instrument was used to assess quality of life. Results: Patients who met the inclusion criteria were enrolled consecutively and were treated with teletherapy using a 60Co source with 1.25 MeV energy. 70.0% of the patients were head and neck cancer patients. No grade 3 - 4 radiation therapy was reported, nor were there any interruptions in radiation treatment due to skin toxicity. Radiation therapy was observed in only 14.0% of patients, and of these, only two patients developed grade 2 toxicity. The perception of quality of life before vs. after radiation therapy remained within an average range of “no effect” (at the start of radiation therapy) to “small effect” (at the end of radiation therapy). Conclusions: This clinical study is the first report of the use of Ocoxin cream® in cancer patients and demonstrates that it is able to prevent radiation therapy and reduce the severity of toxicity of treatment with ionising radiation.Background: The effects of radiation therapy can impact patients’ quality of life, leading to treatment interruptions and therefore sub-optimal outcomes. The main aim was to evaluate the preliminary effects of Ocoxin cream® in the prevention of radiation therapy. Methods: Fifty patients were enrolled in an observational, longitudinal, prospective, single-centre clinical trial in the Department of Radiation Therapy at the National Institute of Oncology and Radiobiology in Havana, Cuba. The Radiation Therapy Oncology Group (RTOG) toxicity criteria were used to classify the radiation therapy, and the Dermatology Life Quality Index (DLQI) instrument was used to assess quality of life. Results: Patients who met the inclusion criteria were enrolled consecutively and were treated with teletherapy using a 60Co source with 1.25 MeV energy. 70.0% of the patients were head and neck cancer patients. No grade 3 - 4 radiation therapy was reported, nor were there any interruptions in radiation treatment due to skin toxicity. Radiation therapy was observed in only 14.0% of patients, and of these, only two patients developed grade 2 toxicity. The perception of quality of life before vs. after radiation therapy remained within an average range of “no effect” (at the start of radiation therapy) to “small effect” (at the end of radiation therapy). Conclusions: This clinical study is the first report of the use of Ocoxin cream® in cancer patients and demonstrates that it is able to prevent radiation therapy and reduce the severity of toxicity of treatment with ionising radiation.

关 键 词：DERMATITIS Radiation Therapy Ocoxin Cream® Quality of Life 

分 类 号：R73[医药卫生—肿瘤]